Kairos Pharma, Ltd. KAPA
1.72
(0.05)
(2.82%)
as of 25 Sep
- Market cap
- $6.1M
- P/E
- 0.0×
Follow KAPA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(92.07%) | (97.99%) | (93.84%) | (113.96%) | |
| (77.46%) | (88.51%) | (85.36%) | (104.32%) | ||
ROIC |
(339.63%) | (346.52%) | (369.94%) | (322.91%) | |
Return on Tangible Assets |
(80.94%) | (104.99%) | (145.54%) | (199.55%) | |
Free Cash Flow per Share |
(1.44) | (1.31) | (1.25) | (1.30) | |
Free Cash Flow |
(4.16) | (3.44) | (3.76) | (3.97) | |
Piotroski F-Score |
2.00 | 3.00 | 3.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
(29.10%) | (29.47%) | (39.14%) | (54.92%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.82 | 0.63 | 0.64 | 0.68 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.44) | (1.31) | (1.25) | (1.30) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates